Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
AAV based gene therapy | 3 |
Therapeutic vaccine | 1 |
Chemical drugs | 1 |
Target |
Mechanism MEK1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 Apr 2020 |
Target |
Mechanism CNGB1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2026 |
Sponsor / Collaborator |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date15 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LODO-141 ( Proteasome ) | Colorectal Cancer More | Preclinical |
Selumetinib sulfate ( MEK1 x MEK2 ) | Neurofibromatosis 1 More | Preclinical |
CaMKII gene therapy (Mount Sinai Medical Center) | Blindness More | Preclinical |
MSU-43085 ( MmpL3 ) | Tuberculosis More | Preclinical |
Rexinoid ( RXRs ) | HER2 Positive Breast Cancer More | Preclinical |